Vamorolone Shows Potential Dual Mechanism as Mineralcorticoid Receptor Antagonist in LIONHEART Study
According to a new announcement, vamorolone (Agamree; Santhera Pharmaceuticals), an FDA-approved therapy for Duchenne muscular dystrophy (DMD), met its primary end point in the LIONHEART study, a 3-arm trial that assessed the mineralocorticoid receptor …